Real-World Analysis of Therapeutic Outcome in Type 1 Diabetes Mellitus at a Tertiary Care Center

Article information

Diabetes Metab J. 2022;46(1):149-153

Publication date (electronic) : 2021 July 6

doi : https://doi.org/10.4093/dmj.2020.0267

Antonia Kietaibl^1,2, Michaela Riedl¹, Latife Bozkurt^,1,3

¹Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

²Department of 5th Internal Medicine with Endocrinology, Rheumatology and Gerontology with Outpatient Department, Clinic Ottakring, Vienna, Austria

³Department of 3rd Internal Medicine with Metabolic Disorders and Nephrology, Clinic Hietzing, Vienna, Austria

Corresponding author: Latife Bozkurt https://orcid.org/0000-0002-3079-9226 Department of 3rd Internal Medicine with Metabolic Disorders and Nephrology, Clinic Hietzing, Wolkersbergenstraße 1, Vienna 1130, Austria E-mail: latife.bozkurt@gesundheitsverbund.at

Received 2020 November 10; Accepted 2021 February 10.

Abstract

Highlights

INTRODUCTION

Intensified therapy is the gold standard for lifelong insulin replacement therapy in type 1 diabetes mellitus (T1DM). A stringent glycaemic control targeting a glycosylated hemoglobin (HbA1c) of <7% leads to a decrease in early-stage microvascular [1] as well as later macrovascular complications [2], and thus, metabolic memory [1,3]. Modern diabetes-related technologies, such as insulin pump treatment and sensor-augmented therapy, are meant to improve glycaemic control and ease diabetes management, particularly by providing new target parameters [4-6]. Continuous subcutaneous insulin infusion (CSII) is associated with decreasing the HbA1c level and lowering the rates of severe hypoglycaemia in comparison with multiple daily injections (MDI) [7-9]. In randomized controlled trials (RCTs) and meta-analyses, even in the absence of improvement in glycaemic control, treatment satisfaction [10], and quality of life [11] were found to increase. Regarding complications, less cases of retinopathy and nerve abnormality were observed with pump therapy [12].

This retrospective real-world analysis aimed to investigate whether insulin pump treatment outclass injections therapy helped in achieving the goals for glycaemic and cardiovascular risk factor control (CVRFC) as suggested by recent evidence. Hence, the hypothesis was that glycaemic control is better with CSII when compared with MDI therapy.

METHODS

For this retrospective study of real-world data, we included 292 patients with diabetes (either T1DM or late-autoimmune diabetes in adults), aged 18 to 80 years, who were treated at the Outpatient Department of Endocrinology and Metabolism, Vienna General Hospital. Their data were analysed between January 2016 and December 2017 (extracted from the latest follow-up visit within the observation period for glycaemic control and CVRFC).

Demographic and clinical data, including body mass index (BMI), sex, date of birth, age, lipid profile, and blood pressure (automated-oscillometric-method) were extracted from patient charts.

For this study, insulin delivery method, data concerning glycaemic control and diabetes-associated-complications were analysed (HbA1c, hypoglycaemia per week, severe hypoglycaemia, sensor-augmented therapy, albuminuria, coronary heart disease [CHD], peripheral artery disease [PAD], ischemic cerebrovascular disease [CBVD], diabetic retinopathy [DRP], and diabetic neuropathy [DNP]). For the analysis of glycaemic control, we used the latest available HbA1c data within the observation period of each individual (the mean follow-up duration was 3.8±12 months). Hypoglycaemia was defined as a measured blood sugar level of ≤70 mg/dL per week (obtained from continuous glucose monitoring [CGM] protocols, handwritten logbooks or the documentation of medical history during the latest outpatient visit) and severe hypoglycaemia, that is, hypoglycaemia requiring external help (extracted from the documentation made during the latest outpatient visit, admission to a hospital and/or documented inpatient stay due to a hypoglycaemic condition). HbA1c was measured using the Haemoglobin Testing System D-10 of BioRad (Hercules, CA, USA; certified method of the National Glycohemoglobin Standardization Program, Diabetes Control and Complications Trial [DCCT] aligned and International Federation of Clinical Chemistry and Laboratory Medicine [IFCC] standardised) [13]. The study was approved by the local ethics committee (EK Nr: 2115/2017) with no informed consent due to retrospective character of the study and was performed in accordance with the Declaration of Helsinki.

RESULTS

Overall, 68 subjects with CSII and 224 patients with MDI were included. The characteristics of the population, including CVRFC and diabetes-associated complications, are listed in Table 1. Table 2 presents the logistic regression data.

Table 1.

Participants’ characteristics and clinical parameters based on insulin delivery method

Table 2.

Linear regression data for the adjustment of possible confounders influencing HbA1c

The latest mean HbA1c in the observational period was not significantly different (CSII 7.57%±1.18% vs. MDI 7.66%± 1.18%, P=0.596; 95% confidence interval [CI], –0.24 to 0.41). To adjust the influence of other factors on the achievement of the primary outcome, a linear regression model was performed by including the variables of age, sex, BMI, diabetes duration and use of sensor-augmented therapy. However, only sex had statistically significant values (P=0.019) that influenced the HbA1c. After adjusting for CSII treatment, sex, age, BMI, diabetes duration, and influence of sensor-augmented therapy, there was no significant difference in HbA1c between the groups (∆0.20%, P=0.282; 95% CI, –0.58 to 0.17) (Table 2).

The median number of hypoglycaemic events per week was significantly lower with pump therapy (P<0.001). Adjustment for possible confounders (sex, age, BMI, diabetes duration, and sensor-augmented therapy) was performed by linear regression, and only the insulin delivery method (CSII vs. MDI) and CGM use showed significant values. Results concerning severe hypoglycaemic events were not significant.

More patients with CSII used sensor-augmented therapy (P=0.003). The iscCGM was applied in both treatment groups in equal rates, whereas rtCGM was employed in the CSII group (Table 1).

The mean BMI within the CSII treatment group was higher (P=0.002), and more patients with pump therapy tended to suffer from obesity (CSII 28.1% vs. MDI 16.3%, P=0.034). The study does not report further significant results concerning CVRFC. The mean differences in the lipid profile, blood pressure and albumin-creatinine ratio between the two treatment groups were not significantly different. Results concerning complications (DRP, PAD, CHD, DNP, CBVD, and albuminuria) were not significantly different between the groups (Table 1).

DISCUSSION

To sum up the most relevant findings of our study, CSII treatment did not outclass MDI with regard to HbA1c, CVRFC, or diabetes-associated complications in this real-world collective. The number of hypoglycaemic events and the use of sensoraugmented therapy with CSII were superior when compared with MDI.

On the basis of this retrospective analysis, we were not able to demonstrate the superiority of insulin pump therapy in controlling mean HbA1c in our real-world setting although evidence suggests its advantage [7-9,14]. Owing to the retrospective nature of this study, we were not able to reproduce the basis of choice and implications of therapy selection for each of the included patients. Higher insulin needs, worse glycaemic control or higher insulin resistance may be the reasons for patients switching to insulin pump treatment. Moreover, the patients’ preference for either of the treatment options and cost-effectiveness are possible biases to be considered. According to a recently published meta-analysis, there may be a decrease in statistically significant results between CSII and MDI once rapidacting analogues are applied [15]. Our study reports that the number of hypoglycaemic events was significantly lower with CSII treatment, and sensor-augmented therapy was applied more often in this group. Evidence shows that rtCGM is more beneficial in the prevention of hypoglycaemia when compared with iscCGM [16], which might explain the detected difference.

Traditional cardiovascular risk factors in combination with hyperglycaemia increase the risk for diabetes-associated complications in T1DM. Herein, we detected a significant difference in BMI between the two treatment groups. This result may either be explained by the unequal ratio (one-fourth vs. three-fourths) or by the differences in baseline BMI. We do not report further significant results concerning CVRFC and prevention of diabetes-associated complications. Since only few studies are available on this aspect, there is an obvious need for further investigations [17].

RCTs involve powerful and highly methodical approaches [18]. However, this might be disadvantageous for some reasons. There are rapid advancements in diabetic technologies, and the evaluation of these changes and their implementation in daily diabetes management might take longer with the conventional concept of RCTs (complex study design, costs, specific populations). Patients may adjust their behaviour, compliance, and motivation after inclusion in studies, resulting in the improvement of glycaemic control without causality, or the subjects may vary significantly from those seen in daily clinical practice. Therefore, real-world evidence might gain importance in evaluating and converting the possible benefits of diabetic treatment options and settings in a faster manner [18,19]. On the other hand, it may be difficult to interpret and develop reliable conclusions for general populations when analysing data from real-world scenarios. Individual preferences, compliance, cost-effectiveness, and insurance coverage might be some of the possible confounders. This issue might be solved by performing prospective longitudinal analysis with matched pairs from clinical registries or databases. Therefore, the presented results need to take into account the limitations of retrospective real-world data and may not be reproducible in a general population [19].

To conclude, in this retrospective analysis of a real-world scenario, insulin pump treatment did not offer significant benefits in terms of glycated haemoglobin or CVRFC. The available evidence suggesting the superiority of CSII might not be reproducible in this real-world collective because of the retrospective nature and the usage of rapid-acting insulin agents.

Future research questions that exploit the potential of the CSII regimen might address a more recent observation period to evaluate whether hybrid-closed and closed loop systems improve glycaemic control when compared with MDI. Furthermore, newer target parameters (time-in-range and glucose variability) may be incorporated in the analysis.

Article information Continued